JOURNAL OF CHEMOTHERAPY

Scope & Guideline

Empowering Innovations in Oncology and Pharmacology

Introduction

Delve into the academic richness of JOURNAL OF CHEMOTHERAPY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1120-009x
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1989 to 2024
AbbreviationJ CHEMOTHERAPY / J. Chemother.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The Journal of Chemotherapy focuses on advancing the understanding and treatment of infectious diseases and cancer through innovative research, clinical trials, and pharmacological studies. The journal emphasizes the importance of chemotherapy and its related fields, including drug resistance, pharmacokinetics, and treatment efficacy.
  1. Chemotherapy Efficacy and Safety:
    Research on the effectiveness and safety profiles of chemotherapy regimens across various cancers, including comparative effectiveness studies of different drug combinations.
  2. Pharmacokinetics and Drug Dosing:
    Studies focusing on the pharmacokinetics of chemotherapeutic agents and antibiotics, including population pharmacokinetic modeling and dosing strategies tailored for specific patient populations.
  3. Drug Resistance Mechanisms:
    Investigation of mechanisms underlying drug resistance in cancer and infectious diseases, including studies on genetic polymorphisms and the role of non-coding RNAs.
  4. Clinical Trials and Real-World Evidence:
    Publication of findings from clinical trials and real-world studies that provide insights into treatment outcomes, adverse effects, and the clinical management of patients receiving chemotherapy.
  5. Infectious Disease Management:
    Research addressing the management of infectious diseases, particularly focusing on antibiotic resistance, treatment strategies, and the role of novel antimicrobial agents.
The Journal of Chemotherapy is adapting to contemporary challenges in oncology and infectious disease management, with several emerging themes reflecting significant shifts in research focus and clinical practice.
  1. Immunotherapy Combinations:
    There is a growing emphasis on studies exploring the combination of immunotherapy with traditional chemotherapy, reflecting the increasing importance of immunotherapeutic strategies in cancer treatment.
  2. Pharmacogenomics and Personalized Medicine:
    Research on pharmacogenomics is gaining traction, as studies investigate how genetic variations affect drug metabolism and response, leading to more personalized chemotherapy regimens.
  3. Antimicrobial Stewardship and Resistance Management:
    An increased focus on antimicrobial stewardship programs and the management of multi-drug resistant pathogens highlights the urgent need for responsible antibiotic use in clinical settings.
  4. Real-World Evidence and Outcomes Research:
    Emerging trends include the collection and analysis of real-world data to assess treatment efficacy and safety, providing more comprehensive insights into patient outcomes outside of controlled clinical trials.
  5. Targeted Therapies and Novel Agents:
    Research into targeted therapies and the development of novel agents is on the rise, as the field shifts towards more specific and effective treatment options for various malignancies.

Declining or Waning

While the Journal of Chemotherapy continues to publish a wide range of impactful research, certain themes appear to be declining in prominence over recent years. These waning scopes indicate shifts in research focus or changes in treatment paradigms.
  1. Traditional Chemotherapy Alone:
    There is a noticeable decline in studies focusing solely on traditional chemotherapy regimens without combination therapies or novel agents, as the field increasingly emphasizes integrated approaches involving immunotherapy and targeted therapy.
  2. Single-Agent Studies:
    Research dedicated to single-agent chemotherapy efficacy is becoming less common, with a trend towards combination therapies that leverage synergistic effects for improved patient outcomes.
  3. Basic Science Research without Clinical Relevance:
    Basic science papers that do not translate into clinical applications or trials are less frequently published, reflecting a shift towards more clinically relevant research that addresses immediate patient care challenges.
  4. Older Antibiotic Classes:
    Research focusing on older classes of antibiotics is decreasing, as new agents and combination therapies gain attention due to rising antibiotic resistance and the need for more effective treatment strategies.

Similar Journals

Drug Discoveries and Therapeutics

Unveiling the future of drug development and therapy.
Publisher: INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENTISSN: 1881-7831Frequency: 6 issues/year

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

Microbial Drug Resistance

Pioneering Insights in Microbial Resistance and Pharmacology
Publisher: MARY ANN LIEBERT, INCISSN: 1076-6294Frequency: 10 issues/year

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

JOURNAL OF VETERINARY MEDICAL SCIENCE

Connecting Scholars and Practitioners in Veterinary Science.
Publisher: JAPAN SOC VET SCIISSN: 0916-7250Frequency: 12 issues/year

JOURNAL OF VETERINARY MEDICAL SCIENCE, published by the Japan Society of Veterinary Science, serves as a critical platform for advancing the field of veterinary medicine. With an ISSN of 0916-7250 and E-ISSN of 1347-7439, this journal covers a broad spectrum of topics relevant to veterinary science, publishing original research, reviews, and case studies that contribute to the scientific knowledge base and clinical practice. Recognized for its quality, the journal has achieved a Q2 ranking in the Veterinary (miscellaneous) category for 2023, placing it within the top 35% of journals in its field as per Scopus rankings. With a convergence of years spanning from 1991 to 2024, it reflects a rich history of scholarly contributions. Researchers, professionals, and students engaged in veterinary science will find valuable insights and advancements within its pages, significantly supporting their work and enhancing veterinary practices globally. The journal is located at the University of Tokyo, and while it does not currently offer open access, it remains an essential resource in veterinary medical literature.

INDIAN JOURNAL OF PHARMACOLOGY

Bridging research and practice in the world of pharmacology.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

CPT-Pharmacometrics & Systems Pharmacology

Bridging the gap between pharmacology and systems science.
Publisher: WILEYISSN: 2163-8306Frequency: 12 issues/year

CPT-Pharmacometrics & Systems Pharmacology, published by WILEY, is a leading open access journal dedicated to advancing the fields of pharmacometrics and systems pharmacology. Since its inception in 2012, it has established itself as a vital resource for researchers and practitioners, boasting a remarkable impact factor and occupying prestigious Q1 quartiles in categories such as Cardiology and Cardiovascular Medicine, Modeling and Simulation, and Pharmacology (Medical). The journal covers a broad spectrum of topics aimed at enhancing the understanding of drug development, efficacy, and patient safety through innovative modeling and simulation approaches. With its consistent ranking in the top tiers of its field, CPT-Pharmacometrics & Systems Pharmacology provides invaluable insights and fosters scholarly dialogue among its audience, including researchers, educators, and students. The journal is accessible to all, promoting knowledge dissemination and collaborative growth in the pharmacology community.

MIKROBIYOLOJI BULTENI

Pioneering Insights in Immunology and Microbiology
Publisher: ANKARA MICROBIOLOGY SOCISSN: 0374-9096Frequency: 4 issues/year

MIKROBIYOLOJI BULTENI, with ISSN 0374-9096, is a prestigious academic journal published by the ANKARA MICROBIOLOGY SOC, located in Ankara, Turkey. Established in 1973, this journal has been a vital conduit for disseminating research in the fields of Immunology, Microbiology, and Infectious Diseases, garnering a reputation as a significant contributor to the scientific community. The journal is currently ranked in the Q3 category within Immunology and Microbiology (miscellaneous), and Infectious Diseases, indicating its impactful presence amidst contemporary research. With access options that may be restricted, MIKROBIYOLOJI BULTENI actively welcomes submissions that advance the understanding of critical microbiological principles and practices, thereby supporting both national and international research efforts. Researchers, professionals, and students are encouraged to explore the latest findings shared in this journal, as it continually shapes the landscape of microbiology and infectious disease studies through its comprehensive and rigorous peer-reviewed publications.

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Exploring breakthroughs in cancer therapy and drug development.
Publisher: SPRINGERISSN: 0344-5704Frequency: 12 issues/year

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

ANTI-CANCER DRUGS

Unveiling Breakthroughs in Cancer Therapeutics
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

CHEMOTHERAPY

Shaping the Future of Pharmacological Sciences
Publisher: KARGERISSN: 0009-3157Frequency: 4 issues/year

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

Advancing Veterinary Care Through Innovative Research
Publisher: WILEYISSN: 0140-7783Frequency: 6 issues/year

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS is a crucial publication in the field of veterinary medicine, dedicated to advancing knowledge and practices related to pharmacology and therapeutic interventions in animals. Published by WILEY, this peer-reviewed journal has been a reliable source of innovative research since its inception in 1978, and it continues to play an integral role in shaping veterinary pharmacology through its commitment to high-quality scientific discourse. With an impact factor reflective of its robust academic standing, the journal is categorized in the Q3 quartile for Pharmacology and Q2 for Veterinary (miscellaneous) as of 2023, highlighting its relevance and significance within these domains. It is indexed in Scopus with commendable rankings, particularly in General Veterinary, where it ranks #45 out of 194, placing it in the 77th percentile. This journal not only offers a platform for original research articles but also caters to the dissemination of practical applications and reviews that are essential for veterinarians, researchers, and students alike in enhancing animal health and welfare. Although not an open-access publication, its contributions remain accessible to those engaged in the veterinary sciences through institutional subscriptions. The journal's enduring legacy and forward-looking approach make it a vital resource for anyone interested in veterinary therapeutics and pharmacology.